Mark focuses his practice on patent prosecution, counseling and diligence for a variety of chemical and life sciences companies. His multidisciplinary background in chemistry enables him to effectively represent clients across a diverse range of technologies.
Cooley advised the underwriters of Septerna, a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, on its upsized $331.2 million initial public offering.
Cooley advised the underwriters of BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases, on its $198 million initial public offering.
